

Reframing Asthma Care : Say No To SABA Monotherapy

Sponsored by Astra Zeneca

Patients continue to suffer preventable asthma attacks, because the traditional approach of using a separate SABA reliever greatly increases the likelihood patients will end up treating their asthma with SABA only – leaving their inflammation unaddressed & put them at risk of exacerbation. The GINA guidelines change was the most important change in 30 years, which now give HCPs and patients the choice of a different class of reliever. The First and Only Anti-Inflammatory Reliever in asthma management delivers efficacy when it matters and reduce exacerbations in mild, moderate and severe asthma patients.

Dr. Sri Wahyu Taher